Trabodenoson: Ph III MATrX-1 data

Top-line data from the double-blind, U.S. Phase III MATrX-1 trial in 303 patients with primary open-angle glaucoma or ocular hypertension showed that once-daily 3% and 6% and twice-daily 4.5% topical